Physician profile
Cory Smith
NPI 1487767596
$15,503.36
in general payments reported to CMS, 2019-2025
65 companies · $2,487 in 2025
The $2,487 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,064 · 2020: $1,798 · 2021: $2,263 · 2022: $2,171 · 2023: $2,443 · 2024: $2,278 · 2025: $2,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,980 · Consulting Fee: $175 · Education: $51.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,980.38 |
| Consulting Fee | $175.00 |
| Education | $51.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,994.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,615.14 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $1,233.14 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,122.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,098.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $886.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $754.16 | 2019-2025 | |
| Amgen INC. | $673.38 | 2019-2025 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $412.56 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $394.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.09 | 2019-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $292.47 | 2020-2025 | Nexletol |
| Smith+Nephew, INC. | $282.57 | 2019 | |
| Amarin Pharma, INC. | $281.73 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.94 | 2019-2022 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $236.85 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $210.51 | 2019-2025 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $191.43 | 2019-2024 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $176.02 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $168.34 | 2023-2025 | Gemtesa |
| Corcept Therapeutics | $166.36 | 2024-2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $147.16 | 2019-2023 | Eliquis |
| Exact Sciences Corporation | $134.40 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $131.28 | 2020 | |
| Axsome Therapeutics, INC. | $130.17 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $124.71 | 2019-2021 | |
| Ossio INC | $122.29 | 2023 | |
| Sunovion Pharmaceuticals INC. | $122.29 | 2021-2022 | |
| Seqirus USA INC | $105.26 | 2022-2025 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Biohaven Pharmaceutical Holding Company Ltd. | $104.13 | 2022 | |
| Shield Therapeutics INC | $102.98 | 2024-2025 | |
| Daiichi Sankyo INC. | $102.25 | 2023-2025 | Injectafer |
| Insulet Corporation | $98.07 | 2025 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $97.65 | 2019-2022 | |
| Sanofi Pasteur INC. | $94.31 | 2019-2025 | |
| Antares Pharma, INC. | $91.68 | 2022-2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.70 | 2024-2025 | Caplyta |
| Dynavax Technologies Corporation | $73.33 | 2024-2025 | Heplisav-B |
| Dexcom, INC. | $72.77 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $71.41 | 2020-2023 | |
| Boston Scientific Corporation | $66.88 | 2020-2025 | Watchman Flx |
| Biohaven Pharmaceuticals, INC. | $63.93 | 2020-2021 | |
| Eisai INC. | $62.49 | 2020-2021 | |
| Nevro Corp. | $53.64 | 2023-2024 | Senza |
| Nestle Healthcare Nutrition INC. | $43.35 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $42.55 | 2023-2025 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $35.02 | 2019-2021 | |
| Mylan Specialty L.P. | $30.21 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $30.10 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $28.31 | 2020-2021 | |
| Novavax INC | $25.07 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Scilex Pharmaceuticals INC. | $24.56 | 2024 | |
| Hikma Pharmaceuticals USA | $24.18 | 2019-2021 | |
| Clarus Therapeutics INC. | $24.16 | 2021 | |
| Phathom Pharmaceuticals, INC. | $23.25 | 2025 | Voquezna |
| Hologic Sales and Service, LLC | $21.35 | 2022 | |
| Corium, LLC | $17.86 | 2023 | Adlarity |
| Kaleo, INC. | $15.14 | 2019 | |
| Edwards Lifesciences Corporation | $15.10 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Arbor Pharmaceuticals, INC. | $14.85 | 2019 | |
| Zyla Life Sciences, INC. | $14.52 | 2019 | |
| Halozyme INC | $14.20 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $11.45 | 2020 | |
| Vistapharm, INC. | $11.44 | 2021 | |
| Cashflow Solutions, LLC | $9.41 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.